AMP and CAP Comment on Palmetto Proposed Guidelines for NGS Testing of Myeloid Disorders

The Association for Molecular Pathology and College of American Pathologists released a letter commenting on Medicare administrative contractor Palmetto GBA's proposed coverage policy for MOLDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies.

The organizations provided a list of genes they said they believe are clinically informative regarding diagnosis and treatment of myeloid disorders and suggested several changes to the coverage policy, including recommendations to refine the list of variants tests would be required to cover and to expand the list of appropriate biopsy specimens and make more frequent testing available.

INDUSTRY NEWS TAGS: Molecular Diagnostics

Share This Post:

Search Billing News

Billing News By TAG

Billing News By DATE